FJ
Jornayvaz, François
Affiliation entities
Research groups
Title | Published in | Access level | OA Policy | Year | Views | Downloads | |
---|---|---|---|---|---|---|---|
S100A9 exerts insulin-independent antidiabetic and anti-inflammatory effects | Science advances | 2024 | 187 | 41 | |||
Diabétologie : ce qui a changé en 2023 | Revue médicale suisse | 2024 | 51 | 4 | |||
Lysophosphatidylinositols Are Upregulated After Human β-Cell Loss and Potentiate Insulin Release | Diabetes | 2024 | 247 | 1 | |||
N ADPH oxidases in healthy white adipose tissue and in obesity : function, regulation, and clinical implications | Obesity | 2024 | 31 | 10 | |||
Gastroparésie diabétique et diabète de type 1 | Revue médicale suisse | 2024 | 39 | 2 | |||
Langerhans Cell Histiocytosis of the Suprasellar Region : Diagnosis on Thyroid Cytology | European thyroid journal | 2024 | 57 | 22 | |||
Gynécologie-obstétrique. Prise en charge et dépistage du diabète gestationnel : ce qui a changé en 2023 | Revue médicale suisse | 2024 | 80 | 1 | |||
Toutes nos différences… | Revue médicale suisse | 2024 | 27 | 2 | |||
Pied diabétique : une prise en charge complexe et multidisciplinaire | Revue médicale suisse | 2023 | 50 | 1 | |||
Nonalcoholic fatty liver disease in type 1 diabetes : where are we? | Polskie Archiwum Medycyny Wewnętrznej | 2023 | 51 | 16 | |||
GLP-1 receptor agonists effect on cognitive function in patients with and without type 2 diabetes | Diabetes & metabolism | 2023 | 57 | 43 | |||
A global research priority agenda to advance public health responses to fatty liver disease | Journal of hepatology | 2023 | 51 | 22 | |||
Diabétologie : ce qui a changé en 2022 | Revue médicale suisse | 2023 | 48 | 0 | |||
Role of Oxidative Stress and Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 in Nonalcoholic Fatty Liver Disease | International journal of molecular sciences | 2023 | 67 | 19 | |||
Circadian organization of lipid landscape is perturbed in type 2 diabetic patients | Cell reports. Medicine | 2023 | 159 | 62 | |||
Stéatopathie non alcoolique (NAFLD) et diabète : le mauvais mariage | Revue médicale suisse | 2023 | 54 | 0 | |||
Unnecessary thyroid surgery rate for suspicious nodule in the absence of molecular testing | European thyroid journal | 2023 | 107 | 37 | |||
Traitement du diabète de type 2 : et si nous revenions à l’essentiel ? | Revue médicale suisse | 2023 | 53 | 0 | |||
A multi–society Delphi consensus statement on new fatty liver disease nomenclature | Journal of hepatology | 2023 | 66 | 14 | |||
The impact of transsphenoidal surgery on pituitary function in patients with non-functioning macroadenomas | Endocrine | 2023 | 89 | 16 | |||
Neuropathie diabétique : mise au point | Revue Médicale Suisse | 2022 | 111 | 75 | |||
Effectiveness of Therapeutic Patient Education Interventions in Obesity and Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials | Nutrients | 2022 | 118 | 97 | |||
NAFLD: From Mechanisms to Therapeutic Approaches | Biomedicines | 2022 | 99 | 102 | |||
Allergie à l’insuline : comment faire ? | Revue médicale suisse | 2022 | 79 | 24 | |||
Non-alcoholic fatty liver disease in type 1 diabetes: prevalence and pathophysiology | Frontiers in endocrinology | 2022 | 69 | 148 | |||
Diabète pancréatoprive | Revue médicale suisse | 2022 | 364 | 39 | |||
Pheochromocytoma presented by Takotsubo, unmasked by accumulation of paroxetine, in a cytochrome poor metabolizer patient: A case report | Thérapie | 2022 | 302 | 1 | |||
Interleukin-18 in metabolism: from mice physiology to human diseases | Frontiers in endocrinology | 2022 | 120 | 98 | |||
Canakinumab in patients with COVID-19 and type 2 diabetes – a multicentre, randomised, double-blind, placebo-controlled trial | EClinicalMedicine | 2022 | 54 | 37 | |||
Sex-specific modulation of circulating growth differentiation factor-15 in patients with type 2 diabetes and/or obesity | Endocrine connections | 2022 | 130 | 55 | |||
(650) Efficacy of therapeutic patient education interventions in metabolic disorders: a systematic review and meta-analysis | 58th EASD Annual Meeting of the European Association for the Study of Diabetes | 2022 | 132 | 7 | |||
Circulating 1,5-anhydroglucitol as a biomarker of ß-cell mass independent of a diabetes phenotype in human subjects | Journal of clinical endocrinology & metabolism | 2022 | 309 | 2 | |||
Moderate to Severe Soft Tissue Diabetic Foot Infections: A Randomized, Controlled, Pilot Trial of Post-debridement Antibiotic Treatment for 10 versus 20 days | Annals of surgery | 2022 | 141 | 177 | |||
NADPH Oxidases Connecting Fatty Liver Disease, Insulin Resistance and Type 2 Diabetes: Current Knowledge and Therapeutic Outlook | Antioxidants | 2022 | 145 | 146 | |||
Dernières recommandations européennes sur les dyslipidémies | Revue médicale suisse | 2022 | 213 | 44 | |||
Hepatic non-parenchymal S100A9-TLR4-mTORC1 axis normalizes diabetic ketogenesis | Nature communications | 2022 | 284 | 65 | |||
Diabète : la pandémie comme révélateur de nos succès/nos failles | Revue médicale suisse | 2022 | 37 | 8 | |||
Diabétologie | Revue médicale suisse | 2022 | 59 | 9 | |||
Hépatopathie et diabète de type 2 | Leading Opinions. Médecine Interne | 2022 | 88 | 0 | |||
Tratamiento podológico del pie diabético | Encyclopédie médico-chirurgicale. Podología | 2022 | 65 | 0 | |||
Systematic Review and Meta-Analysis of the Usefulness of Epicardial Fat Thickness as a Non-Invasive Marker of the Presence and Severity of Nonalcoholic Fatty Liver Disease | Biomedicines | 2022 | 95 | 78 | |||
Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes | Cardiovascular diabetology | 2022 | 60 | 211 | |||
Prise en charge podologique du pied diabétique | Encyclopédie médico-chirurgicale. Podologie | 2022 | 67 | 0 | |||
Growth differentiation factor-15 prevents glucotoxicity and connexin-36 downregulation in pancreatic beta-cells | Molecular and cellular endocrinology | 2022 | 48 | 58 | |||
Le diabète : une pandémie oubliée ? | Revue médicale suisse | 2021 | 86 | 87 | |||
Inhibiteurs du SGLT2 : que des bénéfices? | Revue médicale suisse | 2021 | 310 | 52 | |||
Is routine measurement of the serum C-reactive protein level helpful during antibiotic therapy for diabetic foot infection? | Diabetes, Obesity and Metabolism | 2021 | 133 | 0 | |||
Diabète de type MODY : une entité souvent méconnue | Revue médicale suisse | 2021 | 84 | 36 | |||
Ether lipids, sphingolipids and toxic 1-deoxyceramides as hallmarks for lean and obese type 2 diabetic patients | Acta Physiologica | 2021 | 301 | 3 | |||
Diabétologie | Revue médicale suisse | 2021 | 153 | 2 | |||
Pathophysiology of NASH in endocrine diseases | Endocrine Connections | 2021 | 142 | 79 | |||
Hypothyroidism-Associated Dyslipidemia: Potential Molecular Mechanisms Leading to NAFLD | International journal of molecular sciences | 2021 | 104 | 74 | |||
Diabétologie | Revue médicale suisse | 2020 | 201 | 2 | |||
Diabète: et si on se mettait à la place du patient? | Revue médicale suisse | 2020 | 210 | 0 | |||
Effectiveness and safety of insulin glargine 300 U/mL in insulin-naïve patients with type 2 diabetes after failure of oral therapy in a real-world setting | Diabetes, Obesity and Metabolism | 2020 | 429 | 302 | |||
Thirteen-year trends in the prevalence of diabetes according to socioeconomic condition and cardiovascular risk factors in a swiss population | BMJ Open Diabetes Res Care | 2020 | 296 | 129 | |||
Real-World Effectiveness of Insulin Glargine 300 Initiation in Switzerland | Diabetes, Metabolic Syndrome and Obesity | 2020 | 257 | 125 | |||
La NASH: une complication moins connue mais importante du diabète | Revue médicale suisse | 2020 | 303 | 0 | |||
The GLP-1R agonist liraglutide limits hepatic lipotoxicity and inflammatory response in mice fed a methionine-choline deficient diet | Translational Research | 2020 | 426 | 194 | |||
Quelle place pour les inhibiteurs de la DPP-4 en 2020? | Revue médicale suisse | 2020 | 444 | 0 | |||
Ulcère du pied chez un patient avec un diabète : quelle prise en charge médico-chirurgicale ? | Revue médicale suisse | 2020 | 260 | 1 | |||
Extremely high-dose insulin requirement in a diabetic patient with COVID-19: a case report | BMC Endocrine Disorders | 2020 | 157 | 78 | |||
Diabète après transplantation rénale : mise au point | Revue médicale suisse | 2020 | 317 | 4 | |||
Three versus six weeks of antibiotic therapy for diabetic foot osteomyelitis: A prospective, randomized, non-inferiority pilot trial | Clinical Infectious Diseases | 2020 | 221 | 264 | |||
Insuffisance rénale chronique et nouveaux traitements antidiabétiques : tour d'horizon en 2019 | Revue médicale suisse | 2019 | 577 | 238 | |||
Thirteen-year trends in the prevalence of diabetes in an urban region of Switzerland: a population-based study | Diabetic Medicine | 2019 | 210 | 0 | |||
Salivary cortisol is not associated with incident insulin resistance or type 2 diabetes mellitus | Endocrine Connections | 2019 | 261 | 86 | |||
Faut-il prescrire plus d'inhibiteurs SGLT-2 ? | Revue médicale suisse | 2019 | 259 | 89 | |||
[News in diabetology 2018] | Revue médicale suisse | 2019 | 232 | 74 | |||
Multi-technique comparison of atherogenic and MCD NASH models highlights changes in sphingolipid metabolism | Scientific Reports | 2019 | 388 | 112 | |||
Nonalcoholic fatty liver disease burden | Swiss Medical Weekly | 2019 | 256 | 115 | |||
Prise en charge de la dyslipidémie chez les patients avec un diabète de type 1 | Revue médicale suisse | 2018 | 466 | 18 | |||
Diabétologie | Revue médicale suisse | 2018 | 359 | 37 | |||
Observance thérapeutique et empilage médicamenteux | Revue médicale suisse | 2018 | 322 | 114 | |||
Fibroblast Growth Factor 15/19 - From Basic Functions to Therapeutic Perspectives | Endocrine Reviews | 2018 | 432 | 41 | |||
Transition optimale hôpital-domicile d'un patient diabétique de type 2 : quelques outils | Revue médicale suisse | 2018 | 501 | 64 | |||
Consequences of the Adoption of the IADPSG versus Carpenter and Coustan Criteria to Diagnose Gestational Diabetes: A Before-After Comparison | Experimental and Clinical Endocrinology and Diabetes | 2018 | 460 | 2 | |||
An Overview on Diabetic Foot Infections, including Issues Related to Associated Pain, Hyperglycemia and Limb Ischemia | Current Pharmaceutical Design | 2018 | 435 | 1 | |||
Diabète prégestationnel : une entité de plus en plus fréquente | Revue médicale suisse | 2018 | 459 | 108 | |||
Diabète de type 1, activité physique et nouvelles technologies | Revue médicale suisse | 2018 | 672 | 214 | |||
β-Klotho deficiency protects against obesity through a crosstalk between liver, microbiota, and brown adipose tissue | JCI insight | 2017 | 536 | 236 | |||
Utilité de la mesure en continu de la glycémie chez les patients diabétiques de type 2 | Revue médicale suisse | 2017 | 322 | 0 | |||
Treatment challenges in type 1 diabetes after roux-en-Y gastric bypass | Swiss Medical Weekly | 2017 | 362 | 169 | |||
AMPK activation caused by reduced liver lactate metabolism protects against hepatic steatosis in MCT1 haploinsufficient mice | Molecular Metabolism | 2017 | 369 | 0 | |||
Diabète sucré secondaire à une endocrinopathie : quand y penser ? | Revue médicale suisse | 2017 | 465 | 684 | |||
Diètes cétogènes : la solution miracle ? | Revue médicale suisse | 2017 | 1,120 | 532 | |||
Effects of Ketogenic Diets on Cardiovascular Risk Factors: Evidence from Animal and Human Studies | Nutrients | 2017 | 415 | 0 | |||
Translational Aspects of Diet and Non-Alcoholic Fatty Liver Disease | Nutrients | 2017 | 439 | 0 | |||
Traitement du diabète: quand faire appel au diabétologue? | Revue médicale suisse | 2017 | 324 | 125 | |||
Grip strength is not associated with incident type 2 diabetes mellitus in healthy adults: The CoLaus study | Diabetes Research and Clinical Practice | 2017 | 427 | 0 | |||
Diabétologie | Revue médicale suisse | 2017 | 364 | 91 | |||
GPR40 mediates potential positive effects of a saturated fatty acid enriched diet on bone | Molecular Nutrition and Food Research | 2017 | 479 | 299 | |||
Effects of Antidiabetic Drugs on Gut Microbiota Composition | Genes | 2017 | 404 | 0 | |||
Use of Dipeptidyl-Peptidase IV Inhibitors and Bullous Pemphigoid | Dermatology | 2017 | 392 | 0 | |||
Optimization and testing of dried antibody tube: The EuroFlow LST and PIDOT tubes as examples | Journal of Immunological Methods | 2017 | 353 | 1 | |||
Place des nouveaux antidiabétiques dans la population gériatrique | Revue médicale suisse | 2016 | 377 | 1 | |||
Second-generation antisense oligonucleotides against β-catenin protect mice against diet-induced hepatic steatosis and hepatic and peripheral insulin resistance | FASEB Journal | 2016 | 317 | 0 | |||
Fasting glycaemia to simplify screening for gestational diabetes | BJOG: an International Journal of Obstetrics and Gynaecology | 2016 | 548 | 1 | |||
Diabète gestationnel – quelles sont les approches non médicales ? | Revue médicale suisse | 2016 | 362 | 1 | |||
Comment faire pour prévenir le diabète de type 2 en Suisse? | Revue médicale suisse | 2016 | 383 | 2 | |||
Leptin as a Potential Regulator of FGF21 | Cellular physiology and biochemistry | 2016 | 548 | 199 | |||
Preserving of Postnatal Leptin Signaling in Obesity-Resistant Lou/C Rats following a Perinatal High-Fat Diet | PloS one | 2016 | 452 | 190 | |||
Sécurité cardiovasculaire des antidiabétiques | Revue médicale suisse | 2016 | 373 | 0 | |||
Diabétologie | Revue médicale suisse | 2016 | 333 | 0 | |||
Diabetes Mellitus Is Associated With Reduced High-Density Lipoprotein Sphingosine-1-Phosphate Content and Impaired High-Density Lipoprotein Cardiac Cell Protection | Arteriosclerosis, Thrombosis, and Vascular Biology | 2016 | 524 | 1 | |||
Low birth weight leads to obesity, diabetes and increased leptin levels in adults: the CoLaus study | Cardiovascular Diabetology | 2016 | 481 | 173 | |||
Endocrine causes of nonalcoholic fatty liver disease | World Journal of Gastroenterology | 2015 | 432 | 0 | |||
Free Fatty Acids Impair FGF21 Action in HepG2 Cells | Cellular physiology and biochemistry | 2015 | 508 | 276 | |||
Metformine : nouvelles données pour une ancienne molécule | Revue médicale suisse | 2015 | 369 | 2 | |||
Hepatic insulin resistance and increased hepatic glucose production in mice lacking Fgf21 | Journal of Endocrinology | 2015 | 736 | 308 | |||
Metabolic syndrome and nonalcoholic fatty liver disease: Is insulin resistance the link? | Molecular and Cellular Endocrinology | 2015 | 459 | 1,197 | |||
Classification du diabète : vers une hétérogénéité croissante | Revue médicale suisse | 2015 | 337 | 0 | |||
Ketogenic Diet Impairs FGF21 Signaling and Promotes Differential Inflammatory Responses in the Liver and White Adipose Tissue | PloS one | 2015 | 568 | 240 | |||
Le diabète en 2015 : en augmentation constante, mais avec une offre thérapeutique qui s'élargit | Revue médicale suisse | 2015 | 361 | 1 | |||
Prise en charge des facteurs de risque des maladies cardiovasculaires : qu'est-ce qui a vraiment changé en 15 ans ? | Revue médicale suisse | 2015 | 337 | 1 | |||
Edulcorants artificiels et diabète : faux amis ? | Revue médicale suisse | 2015 | 355 | 0 | |||
ApoA5 knockdown improves whole-body insulin sensitivity in high-fat-fed mice by reducing ectopic lipid content | Journal of Lipid Research | 2015 | 416 | 0 | |||
Serum Vitamin D Concentrations Are Not Associated with Insulin Resistance in Swiss Adults | The Journal of nutrition | 2015 | 499 | 0 | |||
Transition en diabétologie | Revue médicale suisse | 2015 | 510 | 1 | |||
Diets and nonalcoholic fatty liver disease: The good and the bad | Clinical nutrition | 2014 | 617 | 1 | |||
Capsule Commentary on Patrick et al., Trends in Insulin Initiation and Treatment Intensification among Patients with Type 2 Diabetes | Journal of general internal medicine | 2014 | 550 | 1 | |||
Maladies hépatiques chroniques et diabète | Revue médicale suisse | 2014 | 442 | 0 | |||
Traitement combiné d'insuline et d'analogue du GLP-1 : qu'en attendre ? | Revue médicale suisse | 2014 | 520 | 0 | |||
Ostα-/- mice exhibit altered expression of intestinal lipid absorption genes, resistance to age-related weight gain, and modestly improved insulin sensitivity | American Journal of Physiology. Gastrointestinal and Liver Physiology | 2014 | 416 | 0 | |||
Muscle-specific activation of Ca(2+)/calmodulin-dependent protein kinase IV increases whole-body insulin action in mice | Diabetologia | 2014 | 440 | 0 | |||
Cellular mechanisms by which FGF21 improves insulin sensitivity in male mice | Endocrinology | 2013 | 708 | 0 | |||
CGI-58 knockdown sequesters diacylglycerols in lipid droplets/ER-preventing diacylglycerol-mediated hepatic insulin resistance | Proceedings of the National Academy of Sciences | 2013 | 423 | 0 | |||
Increased FGF21 plasma levels in humans with sepsis and SIRS | Endocrine connections | 2013 | 559 | 213 | |||
Non-alcoholic fatty liver disease and insulin resistance: from bench to bedside | Diabetes & metabolism | 2013 | 563 | 0 | |||
Enhanced fasting glucose turnover in mice with disrupted action of TUG protein in skeletal muscle | Journal of Biological Chemistry | 2013 | 447 | 0 | |||
Cellular mechanism by which estradiol protects female ovariectomized mice from high-fat diet-induced hepatic and muscle insulin resistance | Endocrinology | 2013 | 418 | 0 | |||
Sport et diabète de type 1 | Revue médicale suisse | 2013 | 598 | 0 | |||
Inflammation as a potential link between nonalcoholic fatty liver disease and insulin resistance | Journal of Endocrinology | 2013 | 583 | 0 | |||
Thyroid hormone receptor-α gene knockout mice are protected from diet-induced hepatic insulin resistance | Endocrinology | 2012 | 412 | 0 | |||
Development of insulin resistance in mice lacking PGC-1α in adipose tissues | Proceedings of the National Academy of Sciences | 2012 | 358 | 0 | |||
Dissociation of inositol-requiring enzyme (IRE1α)-mediated c-Jun N-terminal kinase activation from hepatic insulin resistance in conditional X-box-binding protein-1 (XBP1) knock-out mice | Journal of Biological Chemistry | 2012 | 388 | 0 | |||
Sommeil et diabète | Revue médicale suisse | 2012 | 458 | 0 |